

Lisa M Baumann Kreuziger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2955564/publications.pdf>

Version: 2024-02-01

69
papers

2,831
citations

331259

21
h-index

189595

50
g-index

69
all docs

69
docs citations

69
times ranked

3113
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 385, 790-802.	13.9	778
2	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 385, 777-789.	13.9	712
3	Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ, The, 2021, 375, n2400.	3.0	250
4	Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Noncritically Ill Hospitalized Patients With COVID-19. JAMA - Journal of the American Medical Association, 2022, 327, 227.	3.8	89
5	Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study. Lancet Haematology, the, 2018, 5, e220-e231.	2.2	76
6	Antithrombotic therapy for left ventricular assist devices in adults: a systematic review. Journal of Thrombosis and Haemostasis, 2015, 13, 946-955.	1.9	61
7	Epidemiology, diagnosis, prevention and treatment of catheter-related thrombosis in children and adults. Thrombosis Research, 2017, 157, 64-71.	0.8	53
8	Not only in trauma patients: hospital-wide implementation of massive transfusion protocol. Transfusion Medicine, 2014, 24, 162-168.	0.5	41
9	Randomized trials of therapeutic heparin for COVID-19: A meta-analysis. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12638.	1.0	39
10	Mechanical circulatory support: balancing bleeding and clotting in high-risk patients. Hematology American Society of Hematology Education Program, 2015, 2015, 61-68.	0.9	36
11	Management of anticoagulation and antiplatelet therapy in patients with left ventricular assist devices. Journal of Thrombosis and Thrombolysis, 2015, 39, 337-344.	1.0	36
12	Management of the Bleeding Patient Receiving New Oral Anticoagulants: A Role for Prothrombin Complex Concentrates. BioMed Research International, 2014, 2014, 1-7.	0.9	35
13	Anticoagulation practice patterns in COVID-19: A global survey. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 969-983.	1.0	35
14	Selection Criteria for Internal Medicine Residency Applicants and Professionalism Ratings During Internship. Mayo Clinic Proceedings, 2011, 86, 197-202.	1.4	33
15	Is prophylaxis required for delivery in women with factor VII deficiency?. Haemophilia, 2013, 19, 827-832.	1.0	33
16	New anticoagulants. Journal of Trauma and Acute Care Surgery, 2012, 73, 983-992.	1.1	28
17	A RIETE registry analysis of recurrent thromboembolism and hemorrhage in patients with catheter-related thrombosis. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2015, 3, 243-250.e1.	0.9	28
18	Systematic review of anticoagulant treatment of catheter-related thrombosis. Thrombosis Research, 2015, 136, 1103-1109.	0.8	28

#	ARTICLE	IF	CITATIONS
19	Antithrombotic therapy management of adult and pediatric cardiac surgery patients. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 2133-2146.	1.9	28
20	An MLL-SEPT9 fusion and t(11;17)(q23;q25) associated with de novo myelodysplastic syndrome. <i>Leukemia Research</i> , 2007, 31, 1145-1148.	0.4	26
21	A practical approach to evaluating postoperative thrombocytopenia. <i>Blood Advances</i> , 2020, 4, 776-783.	2.5	24
22	Risk of venous thromboembolism after COVID-19 vaccination. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1638-1644.	1.9	24
23	Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2019, 12, 10-14.	0.6	23
24	Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapiesâ€”TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2068-2081.	1.9	23
25	Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study. <i>Blood Advances</i> , 2021, 5, 5546-5553.	2.5	23
26	Management of Bleeding Associated with Dabigatran and Rivaroxaban: A Survey of Current Practices. <i>Thrombosis Research</i> , 2013, 132, e161-e163.	0.8	19
27	Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID) Tj ETQq1 1 0,784314 rgBT /Ove <i>Trials</i> , 2021, 22, 202.	0.7	19
28	Monitoring anticoagulation in patients with an unreliable prothrombin time/international normalized ratio. <i>Blood Coagulation and Fibrinolysis</i> , 2014, 25, 232-236.	0.5	16
29	The impact of Agent Orange exposure on presentation and prognosis of patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 63-66.	0.6	14
30	Hypertriglyceridemia during hospitalization independently associates with mortality in patients with COVID-19. <i>Journal of Clinical Lipidology</i> , 2021, 15, 724-731.	0.6	14
31	Race, rituximab, and relapse in TTP. <i>Blood</i> , 2022, 140, 1335-1344.	0.6	13
32	Anticoagulation in hospitalized patients with COVID-19. <i>Blood</i> , 2022, 140, 809-814.	0.6	12
33	Adult and pediatric mechanical circulation: a guide for the hematologist. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 507-515.	0.9	11
34	Wide Variation in Duration of Anticoagulation after Catheter-Related Thrombosis: A Venous Thromboembolism Network US Multicenter Retrospective Cohort Study. <i>Blood</i> , 2018, 132, 1248-1248.	0.6	11
35	A Novel PF4-Dependent P-Selectin Expression Assay (PEA) Facilitates Early Detection of Pathogenic HIT Antibodies: Implications for Diagnosis and Treatment of HIT. <i>Blood</i> , 2016, 128, 2599-2599.	0.6	11
36	RAD51 and XRCC3 polymorphism frequency and risk of myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2008, 83, 822-823.	2.0	10

#	ARTICLE	IF	CITATIONS
37	Ventricular assist device thrombosis: Mind your P's & Q's" Pumps, patients, and pills. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 153, 1503-1506.	0.4	10
38	Risk of pulmonary emboli after removal of an upper extremity central catheter associated with a deep vein thrombosis. <i>Blood Advances</i> , 2021, 5, 2807-2812.	2.5	10
39	Consensus Statement: Hemostasis Trial Outcomes in Cardiac Surgery and Mechanical Support. <i>Annals of Thoracic Surgery</i> , 2022, 113, 1026-1035.	0.7	9
40	Management of incidental splanchnic vein thrombosis in cancer patients. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 318-320.	0.9	8
41	Treatment of catheter-related thrombosis in patients with hematologic malignancies: A Venous thromboEmbolism Network U.S. retrospective cohort study. <i>Thrombosis Research</i> , 2021, 202, 155-161.	0.8	8
42	Anti-Xa monitoring of low-molecular-weight heparin in adult patients with cancer. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 206-207.	0.9	7
43	Red blood cell transfusion does not increase risk of venous or arterial thrombosis during hospitalization. <i>American Journal of Hematology</i> , 2021, 96, 218-225.	2.0	7
44	The impact of Agent Orange exposure on prognosis and management in patients with chronic lymphocytic leukemia: a National Veteran Affairs Tumor Registry Study. <i>Leukemia and Lymphoma</i> , 2018, 59, 1348-1355.	0.6	6
45	Symptomatic pulmonary embolus after catheter removal in children with catheter related thrombosis: A report from the CHAT Consortium. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 133-137.	1.9	6
46	Balancing bleeding in brain metastases. <i>Blood</i> , 2015, 126, 432-433.	0.6	5
47	A prospective cohort study of catheter-related thrombosis in cancer patients treated with 1 month of anticoagulation after catheter removal. <i>Blood Coagulation and Fibrinolysis</i> , 2022, 33, 171-175.	0.5	5
48	Use of recombinant human antithrombin concentrate in pregnancy. <i>International Journal of Women's Health</i> , 2013, 5, 583.	1.1	4
49	Heparin Monitoring with an Anti-Xa Protocol Compared to Activated Clotting Time in Patients on Temporary Mechanical Circulatory Support. <i>Annals of Pharmacotherapy</i> , 2022, 56, 513-523.	0.9	4
50	Adequacy of hemostatic resuscitation improves therapeutic efficacy of recombinant activated factor VII and reduces reexploration rate for bleeding in postoperative cardiac surgery patients with refractory hemorrhage. <i>Annals of Cardiac Anaesthesia</i> , 2019, 22, 388.	0.3	4
51	Lack of efficacy of pyridoxine (vitamin B6) treatment in acquired idiopathic sideroblastic anaemia, including refractory anaemia with ring sideroblasts. <i>European Journal of Haematology</i> , 2011, 86, 512-516.	1.1	3
52	Perinephric extramedullary haematopoiesis in primary myelofibrosis. <i>British Journal of Haematology</i> , 2012, 157, 157-157.	1.2	3
53	North American Physician Practice Patterns in the Management of Anticoagulation in Pregnancy. <i>Journal of Women's Health</i> , 2021, 30, 829-836.	1.5	3
54	Bariatric surgery in patients with advanced heart failure: A proposed multi-disciplinary pathway for surgical care in medically complex patients. <i>Surgery</i> , 2021, 170, 659-663.	1.0	3

#	ARTICLE	IF	CITATIONS
55	Optimal Timing for Removal of an Upper Extremity Central Catheter When Associated with a Deep Vein Thrombosis: A Venous Thromboembolism Network US Multicenter Retrospective Cohort Study. <i>Blood</i> , 2019, 134, 325-325.	0.6	3
56	Patient Safety Indicator Rarely Identifies Problems with Quality of Care in Perioperative Venous Thromboembolism. <i>Journal of Hospital Medicine</i> , 2020, 15, 75-80.	0.7	3
57	Thromboinflammatory biomarkers and D-dimer in a biracial cohort study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12632.	1.0	3
58	Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase: A real world study. <i>Leukemia Research</i> , 2020, 94, 106368.	0.4	2
59	79-Year-Old Man With Fever, Malaise, and Jaundice. <i>Mayo Clinic Proceedings</i> , 2009, 84, 281-284.	1.4	1
60	Management of cancer-associated thrombosis with thrombocytopenia: Impact of the ISTH guidance statement. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12726.	1.0	1
61	Physician perceptions and use of reduced-dose direct oral anticoagulants for extended phase venous thromboembolism treatment. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12740.	1.0	1
62	Thromboprophylaxis alerts for physicians did not reduce VTE in at-risk patients after discharge. <i>Annals of Internal Medicine</i> , 2013, 159, JC11.	2.0	0
63	Monitoring Platelet Function in Children With Ventricular Assist Devices: The Devil Is in the Details. <i>ASAIO Journal</i> , 2019, 65, 104-105.	0.9	0
64	Relieving Inhibition of Prothrombinase By TFP: a Procoagulant Activity of Unfractionated, Low Molecular Weight, and Nonanticoagulant Heparins. <i>Blood</i> , 2014, 124, 1478-1478.	0.6	0
65	Incidence of catheter-related venous thromboembolism in peripherally inserted central venous catheters vs tunneled chest central venous catheters in patients with hematologic malignancies. <i>Journal of Clinical Oncology</i> , 2015, 33, e20684-e20684.	0.8	0
66	Agent Orange Exposure Does Not Predict for Shorter Overall Survival in Patients with Chronic Lymphocytic Leukemia: A National Veteran Affairs Tumor Registry Study. <i>Blood</i> , 2016, 128, 5568-5568.	0.6	0
67	79-year-old man with fever, malaise, and jaundice. <i>Mayo Clinic Proceedings</i> , 2009, 84, 281-4.	1.4	0
68	Prospective Cohort of Catheter Related Thrombosis in Patients Treated with One Month of Anticoagulation after Catheter Removal. <i>Blood</i> , 2020, 136, 36-37.	0.6	0
69	Late relapses in diffuse large B-cell lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2011, 9, 709-10.	0.3	0